Raising Antibody Validation Standards with Knockout Technology Webinar
Learn how we are raising industry quality standards by using improved technology to manufacture and validate our products.
To ensure that our antibodies are specific and provide reproducible results, we have recently introduced knockout (KO) validation at scale. Using human KO* cell lines, we are developing a growing range of KO-validated antibodies, including many recombinant monoclonal antibodies.
*We validate antibodies using KO cell lines from Horizon Discovery.
About the Presenter
Dr Alejandra Solache joined Abcam in 2013 as Head of Reagents, Product Development and Manufacturing globally. She is responsible for managing the output of the Abcam Cambridge, Hangzhou and Bristol laboratories, specifically new product development, core reagents and R&D. She also plays a key role in developing our innovation strategy.
Prior to joining Abcam she held various positions at EMD-Millipore, latterly as R&D Director, leading the Antibody and Assay Development teams. She gained expertise in immunology, cell signaling and cell biology through postdoctoral fellowships at UCSF and the Trudeau Institute.
How antibody manufacture affects quality
Antibody validation methods
Our knockout validation initiative
Best practices to ensure reproducible results